Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Dovitinib with Gemcitabine and Nab-Paclitaxel in Advanced Solid Tumors and Pancreatic Cancer
NCT02048943Phase 1Withdrawn
- Sponsor
- Roswell Park Comprehensive Cancer Center
- Start
- Mar 2015
- Primary completion
- Nov 2015
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, open-label trial of dovitinib in pancreatic adenocarcinoma (PDAC) and solid tumor, sponsored by Roswell Park Comprehensive Cancer Center. Planned start Mar 2015; status: withdrawn.
02
Drugs
dovitinib
03
Conditions
pancreatic adenocarcinoma (PDAC)solid tumor
Beyond the preview
Go deeper on NCT02048943.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02048943.